How-VMAT2-Inhibitors-Are-Reshaping-Tardive-Dyskinesia-Care

By Gina ShawFor decades, managing tardive dyskinesia (TD) had been defined more by avoidance than treatment. Clinicians focused on minimizing exposure to antipsychotic medications, switching agents, or lowering doses—strategies that often came at the expense of psychiatric stability. Until recently, there were no FDA-approved therapies specifically indicated for TD, and remission was rarely part of the conversation.“Tardive dyskinesia was historically viewed as a medication-induced a